{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.6","upperLimit":"NA","value":"14.1"},{"comment":"Insufficient number of participants with events","groupId":"OG002","lowerLimit":"1.4","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events","groupId":"OG005","lowerLimit":"6.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"35"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Advanced and/or metastatic non-small cell lung cancer with disease progression on or after an immune checkpoint inhibitor-containing regimen and a platinum-containing regimen, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations, and who were not amenable to curative treatment","id":"OG000","title":"Non-small Cell Lung Cancer"},{"description":"Microsatellite instability-high or mismatch repair deficient colorectal cancer that was unresectable or metastatic","id":"OG001","title":"Colorectal Cancer"},{"description":"Recurrent or metastatic cutaneous squamous cell carcinoma that was not curable by surgery or radiation and in second line if refractory or relapsed after a checkpoint inhibitor-containing regimen and radiotherapy was not feasible","id":"OG002","title":"Cutaneous Squamous Cell Carcinoma"},{"description":"Advanced hepatocellular carcinoma after recurrence or failure of an immune checkpoint inhibitor (not applicable in France)","id":"OG003","title":"Hepatocellular Carcinoma"},{"description":"Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent","id":"OG004","title":"Metastatic Castration-resistant Prostate Cancer"},{"description":"Advanced recurrent ovarian cancer after recurrence or failure on the last platinum-based therapy within 6 months","id":"OG005","title":"Ovarian Cancer"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Day 1 up to approximately 2 years and 2 months","title":"Time to Response According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"months"}